Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853772 | 0.82 | MAPT (0.43) | MAPTHSD17B10ALDH1A1CNR1AOC3 | |
| SCHEMBL4860253 | 0.81 | MAPT (0.41) | MAPTHSD17B10ALDH1A1PRKCINR3C2 | |
| SCHEMBL3353364 | 0.79 | HCAR3 (0.48) | S1PR1S1PR3HSD17B10HCAR3AOC3 | |
| SCHEMBL4864053 | 0.78 | MAPT (0.37) | MAPTHSD17B10ALDH1A1PRKCINR3C2 | |
| Hydrochloric Acid SCHEMBL3855650 | 0.78 | HCAR3 (0.47) | S1PR1S1PR3HSD17B10HCAR3AOC3 | |
| SCHEMBL23015809 | 0.76 | KDM4E (0.54) | MAPTHSD17B10ALDH1A1ARPRKCI | |
| SCHEMBL27627388 | 0.75 | PRKCI (0.63) | MAPTHSD17B10ALDH1A1ARPRKCI | |
| SCHEMBL4851904 | 0.74 | NR3C2 (0.47) | MAPTNR3C2 | |
| SCHEMBL3352698 | 0.74 | HCAR3 (0.60) | S1PR1S1PR3MAPTHCAR3ALDH1A1 | |
| SCHEMBL16968859 | 0.73 | AR (0.39) | MAPTHSD17B10ALDH1A1ARPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | S1PR1 777/4885S1PR3 618/4885MAPT 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.